LUPUS NEPHRITIS (LN)

This early-phase study tests a new cell treatment called YTS109 in 18 adults with severe autoimmune diseases like lupus and vasculitis that have not responded to standard therapies. Participants receive a single infusion of these specially engineered cells. The main goal is to ch…

This study tests an experimental oral drug, HSK39297, in people with lupus nephritis – a serious kidney complication of lupus. About 105 adults will receive either 200 mg, 300 mg, or a placebo daily for several weeks. The main goal is to see if the drug reduces protein in the uri…

This study tests a new drug called HLX79, given together with rituximab, for people with active kidney inflammation (glomerulonephritis) from membranous nephropathy or lupus. About 24 adults will receive either HLX79 or a placebo, plus rituximab, to see if the combination is safe…

This early-stage study tests experimental bispecific antibody drugs in people with lupus nephritis, a serious kidney complication of lupus. The main goal is to see if the drugs are safe and tolerable over the long term. About 90 participants with hard-to-treat or relapsed disease…

This early-stage study tests a new drug called HB2198 in about 30 adults with moderate-to-severe lupus, including kidney inflammation. The drug is designed to target and deplete certain immune cells (B cells) that drive the disease. The main goals are to check safety, find the ri…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and Sjogren's syndrome. The main goal is to check if the treatment is safe, and also to see if it helps control the disease. Participants receive a singl…

This early study tests a new cell treatment called YTS109 in 18 adults with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. Participants get a single infusion of these specially designed cells. The main goal is to see if the treatme…

This early-phase study tests whether a new drug called ONTO1 is safe for people with lupus nephritis or systemic lupus erythematosus (SLE). About 61 participants will receive ONTO1 alongside standard lupus treatments like mycophenolate mofetil. The goal is to find the highest saf…

This study tests whether newer biologic drugs (belimumab or telitacicept) can control active lupus kidney disease better than the standard medication mycophenolate mofetil. About 50 adults with biopsy-confirmed lupus nephritis will receive one of three treatments for 6 months. Th…

This study tests a new treatment using a patient's own immune cells, modified to target and attack lupus-causing cells. It is for people with severe lupus that hasn't responded to standard therapies. The goal is to see if this approach can safely control the disease and reduce sy…

This study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. The goal …

This study is a fully online registry for adults and children with lupus. It aims to collect information about diagnosis, treatment, and quality of life through surveys every six months. No travel is required—everything is done from home. The goal is to better understand lupus an…